A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
收藏DataCite Commons2025-09-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006462/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to demonstrate the safety and effectiveness of abiraterone acetate when co-administered with prednisone in patients with chemo-naive metastatic castration resistant prostate Cancer (mCRPC).
本研究旨在验证醋酸阿比特龙与泼尼松联合给药时，在未经化疗的转移性去势抵抗性前列腺癌（mCRPC）患者中的安全性与有效性。
提供机构：
Vivli
创建时间：
2020-11-03
